Disease-modifying activity of ruxolitinib in a patient with <i>JAK2</i>-negative CMML-2
Silvan Francke(Klinik und Poliklinik für Psychotherapie und Psychosomatik), Uwe Platzbecker(National Center for Tumor Diseases), Gerhard Ehninger(University Hospital Carl Gustav Carus), Uta Oelschlaegel(University Hospital Carl Gustav Carus), Martin Bornhäuser(Technische Universität Dresden), Manja Meggendorfer(Université Paris-Sud), Torsten Haferlach(Martin Luther Christian University), Ekaterina Balaian(University Hospital Carl Gustav Carus), Anna Mies(University Hospital Carl Gustav Carus), Silke Gloaguen
Cited by 5
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k